Management of enteric fever

Reading File

Finding Sources

Searching PubMed

"enteric fever" AND treatment

Reading File

Finding Sources

Reading File

Finding Sources

I now have comprehensive data. Let me compile the full answer from Harrison's 22e (2025), Goldman-Cecil, Red Book, and Tintinalli.

Management of Enteric Fever (Typhoid/Paratyphoid)

Enteric fever is caused by Salmonella Typhi (typhoid fever) and S. Paratyphi A, B, and C (paratyphoid fever). Without treatment, case-fatality is 10-30%; prompt appropriate antibiotics reduce this to <1%.

1. Assessment and Triage

Hospitalization criteria:

Persistent vomiting, diarrhea, or abdominal distension
Altered sensorium (delirium, obtundation, stupor, coma)
Shock
Signs of intestinal hemorrhage or perforation

Uncomplicated enteric fever can be managed as an outpatient with oral antibiotics and antipyretics. Hospitalized patients require parenteral therapy plus supportive care (IV rehydration, blood transfusion if needed for GI losses).

2. Antibiotic Therapy

The key principle in 2025 is that antibiotic selection must be driven by the likely resistance pattern based on travel history, not by traditional first-line agents.

Resistance Overview

Pattern	Resistance Profile	Common Source
Fully susceptible	Sensitive to all agents	Older/isolated strains
MDR (multidrug-resistant)	Resistant to chloramphenicol, ampicillin, TMP-SMX	Indian subcontinent, Africa
DSC/Fluoroquinolone-resistant	Decreased susceptibility to ciprofloxacin (MIC ≥0.125)	Indian subcontinent, SE Asia
XDR (extensively drug-resistant)	Resistant to ceftriaxone + all above; susceptible only to azithromycin and carbapenems	Pakistan (ongoing since 2016)

A 2022 systematic review of 27 RCTs found no statistically significant difference between ceftriaxone, fluoroquinolone, and azithromycin in treatment failure, microbiologic failure, relapse, or adverse events. - Harrison's Principles of Internal Medicine 22E (2025), p. 1361

Drug Regimens (Adults) - Harrison's 22e Table 171-1

Indication	Agent	Dose (Route)	Duration
Empirical treatment	Ceftriaxone^a	2 g/d IV	10-14 days
	Ciprofloxacin^b	500 mg bid PO or 400 mg q12h IV	5-7 days
	Azithromycin^c	1 g/d PO	10 days
Fully susceptible - Optimal	Ceftriaxone	2 g/d IV	10-14 days
	Ciprofloxacin	500 mg bid PO or 400 mg q12h IV	5-7 days
Fully susceptible - Alternative	Azithromycin	1 g/d PO	5 days
	Amoxicillin	1 g tid PO or 2 g q6h IV	14 days
	Chloramphenicol	25 mg/kg tid PO or IV	14-21 days
	TMP-SMX	Standard dosing	14 days
MDR (not XDR)	Ceftriaxone	2 g/d IV	10-14 days
	Azithromycin	1 g/d PO	5-7 days
DSC/Fluoroquinolone-resistant	Ceftriaxone	2 g/d IV	10-14 days
	Azithromycin	1 g/d PO	5-7 days
XDR	Meropenem or Imipenem	Standard carbapenem dosing	10-14 days
	Azithromycin	1 g/d PO	5-7 days

^a Cefotaxime and (oral) cefixime are alternatives to ceftriaxone for MDR strains; cefixime may increase time to defervescence. ^b Fluoroquinolones should NOT be used empirically in travelers from South Asia or areas with known DSC/resistance. ^c Azithromycin: uncomplicated disease can be treated with 1 g once then 500 mg/d for 7 days.

Harrison's Principles of Internal Medicine 22E (2025), p. 1361

3. Empirical Treatment by Travel History

No travel to South Asia / Pakistan: Ciprofloxacin or ceftriaxone acceptable
Travel from Indian subcontinent or SE Asia: Avoid fluoroquinolones empirically; use ceftriaxone or azithromycin
Travel from Pakistan (especially Sindh province): Suspect XDR; treat with carbapenem ± azithromycin until susceptibilities return
Red Book note: Most typhoid diagnosed in US travelers is fluoroquinolone nonsusceptible - do not use fluoroquinolones as empiric therapy for returning South Asia travelers

Therapy should continue for at least 10 days or 5 days after fever resolution.

4. Severe / Complicated Enteric Fever

Adjunctive Corticosteroids

Dexamethasone is indicated in critically ill patients (shock, delirium, obtundation, stupor, coma):

Dexamethasone: 3 mg/kg IV loading dose, then 1 mg/kg IV every 6 hours for 8 doses (48 hours total)
Evidence: A landmark double-blind RCT in critically ill Indonesian patients showed mortality fell from 55% to 10% when dexamethasone was added to chloramphenicol
Steroid treatment beyond 48 hours may increase relapse rate

Enteric fever with severe toxemia remains one of the few bacterial infections where corticosteroids are indicated. - Harrison's Principles of Internal Medicine 22E (2025), p. 1361; Red Book 2021, p. 1024

Intestinal Perforation

Immediate surgical consultation
Broad-spectrum antibiotics covering gram-negatives and anaerobes
IV fluid resuscitation

Intestinal Hemorrhage

IV fluids, blood transfusion as needed
Conservative management; surgery if uncontrolled

5. Chronic Carrier State (2-5% of patients)

Chronic carriage persists >1 year, typically in the gallbladder. Eradication:

Fluoroquinolone-susceptible strains: Ciprofloxacin (or norfloxacin) orally x 4 weeks - ~80% eradication rate
Fluoroquinolone-resistant strains: Azithromycin orally x 4 weeks (limited data) or amoxicillin if susceptible (lower eradication rate)
Anatomic abnormality (gallstones, urinary stones): antibiotic therapy + surgical correction (cholecystectomy) often required

6. Pediatric Considerations (Red Book 2021)

Use parenteral third-generation cephalosporin or azithromycin empirically for MDR (non-XDR) S. Typhi
For XDR typhoid (Pakistan-acquired): carbapenem ± azithromycin
Dexamethasone: same regimen as adults (3 mg/kg then 1 mg/kg q6h x 48h) for severe disease with delirium, obtundation, stupor, coma, or shock
Uncomplicated disease: 7-10 days minimum; amoxicillin or TMP-SMX (if susceptible) should be given for 14 days
Relapse occurs in up to 17% within 4 weeks; immunocompromised patients require longer treatment

7. Isolation and Infection Control

Standard + contact precautions for diapered/incontinent patients
For enteric fever: continue precautions until 3 consecutive negative stool cultures obtained at least 48 hours after stopping antibiotics
For XDR typhoid: contact precautions per MDR organism guidelines throughout hospital stay
Notify public health authorities

8. Relapse

Occurs in 2-17% of treated patients (higher risk with immunocompromise)
Usually milder than primary illness
Re-treat with same or alternative agent based on susceptibility
Relapse rates appear lower with azithromycin than fluoroquinolones or ceftriaxone

9. Vaccination (Prevention)

Vaccine	Route	Age	Dosing	Efficacy	Booster
Ty21a (live oral)	Oral	≥6 years	4 doses on days 1,3,5,7	~50% at 2.5-3 yrs	Every 5 years
Vi CPS (polysaccharide)	IM	≥2 years	Single dose	~55% at 3 yrs	Every 2 years
Typbar TCV (conjugate)	IM	≥6 months	Single 0.5 mL dose	79-95%, up to 7 yrs	Not yet defined

Typhoid conjugate vaccines (TCV) are recommended by WHO for endemic countries. No licensed vaccine exists for paratyphoid. Vaccination does not replace safe food/water precautions.

Summary Algorithm

Suspected Enteric Fever
        |
        ├─ Cultures (blood, stool, ± bone marrow)
        ├─ Assess severity
        |
        ├─ UNCOMPLICATED → Oral azithromycin or cefixime (outpatient)
        |
        └─ COMPLICATED / hospitalized
                |
                ├─ Origin South Asia/SE Asia → Ceftriaxone IV (avoid FQs)
                ├─ Pakistan origin → Carbapenem ± azithromycin (XDR risk)
                ├─ Fully susceptible → Ciprofloxacin or ceftriaxone
                |
                ├─ Critically ill (shock, altered consciousness)?
                |       └─ ADD Dexamethasone (3 mg/kg → 1 mg/kg q6h × 8 doses)
                |
                └─ Perforation/hemorrhage → Surgery + broad-spectrum ABx

Key sources: Harrison's Principles of Internal Medicine 22E (2025) | Goldman-Cecil Medicine | Red Book 2021 | Tintinalli's Emergency Medicine

This is a shared conversation. Sign in to Orris to start your own chat.